Appointment of Director of Operations
LUND, Sweden — /September 2, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of a new Director of Operations, Johanna Asklin, PhD, an experienced professional project and portfolio manager in the life sciences.
“We are pleased to welcome Johanna, who has been involved in SAGA’s journey from the very beginning when we were still based in academia and filing the first patents.” – Lao Saal, Co-Founder and CEO.
Dr. Asklin has over 12 years’ experience in commercial project management and business development, beginning at Intercell AG (now Valneva) in vaccine development and later at the Danish Statens Serum Institut from 2008-2014. Prior to joining SAGA, she was Head of Life Science at LU Innovation for five years with a focus on the commercialization of cancer research, during which time she also served on SAGA’s Board of Directors. Johanna earned her PhD in immunology and microbiology from Gothenburg University in 2006.
“SAGA is building momentum with biopharma and hospital lab customers, and with Johanna’s experience and familiarity with our company, I am sure she will be very effective in driving operations and optimizing throughput and efficiencies to meet the demand.” – Anthony George, Co-Founder and CTO.
Contact: CEO Lao Saal, MD PhD. firstname.lastname@example.org Phone: +46 (0)70 – 888 52 61
About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.